Patent: 10,675,286
✉ Email this page to a colleague
Summary for Patent: 10,675,286
| Title: | Heterocyclic compounds and uses thereof |
| Abstract: | Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. |
| Inventor(s): | Kutok; Jeffery L. (Natick, MA), Winkler; David G. (Arlington, MA), Palombella; Vito J. (Needham, MA) |
| Assignee: | Infinity Pharmaceuticals, Inc. (Cambridge, MA) |
| Application Number: | 15/672,964 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,675,286
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | For Injection | 125514 | 09/04/2014 | ⤷ Try a Trial | 2034-03-19 |
| Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | Injection | 125514 | 01/15/2015 | ⤷ Try a Trial | 2034-03-19 |
| Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 12/22/2014 | ⤷ Try a Trial | 2034-03-19 |
| Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 10/04/2017 | ⤷ Try a Trial | 2034-03-19 |
| Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 08/27/2021 | ⤷ Try a Trial | 2034-03-19 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
